Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Metabolic stability and tumor inhibition of bombesin/GRP receptor antagonists
Ist Teil von
Peptides (New York, N.Y. : 1980), 1992-03, Vol.13 (2), p.401-407
Ort / Verlag
New York, NY: Elsevier Inc
Erscheinungsjahr
1992
Quelle
ScienceDirect
Beschreibungen/Notizen
Small cell lung cancers (SCLC) synthesize and secrete bombesin/gastrin releasing peptide (BN/GRP). The autocrine growth cycle of BN/GRP in SCLC can be disrupted by BN/GRP receptor antagonists such as [Psi
13,14]BN. Here several BN analogues were solid-phase synthesized and incubated with intact SCLC cells at 37°C in RPMI medium in a time-course fashion (0–1080 minutes) to determine enzymatic stability. The proteolytic stability of the compounds was determined by subsequent HPLC analysis. The metabolic half-life ranged from 154 minutes to 1388 minutes for the six analogues studied. [Psi
13,14]BN was found to be very stable to metabolic enzymes (
T
1
2
= 646
mm
) and also inhibited SCLC xenograft formation in vivo in a dose-dependent manner. When [Psi
13,14]BN was incubated with NCI-H345 cells, it inhibited
125I-GRP binding with an IC
50 value of 30 nM. These data suggest that BN/GRP receptor antagonists such as [Psi
13,14]BN may be useful for the treatment of SCLC.